The mutational profiles provide insights into clonal evolution occuring during tumor progression under therapy: Molecular profiling revealed recurrent genomic alterations in genes frequently altered in ccRCC [14], including VHL, SETD2, and BAP1. Deletions of the VHL tumor suppressor gene are occuring early during tumorigenesis of ccRCC [16]. Here, VHL is linked to nonpapillary renal cell carcinoma.